Keith Wayne Ward - 25 Aug 2023 Form 4 Insider Report for Skye Bioscience, Inc. (SKYE)

Role
Director
Signature
/s/ Kaitlyn Arsenault
Issuer symbol
SKYE
Transactions as of
25 Aug 2023
Net transactions value
$0
Form type
4
Filing time
29 Aug 2023, 18:17:30 UTC
Previous filing
09 Jan 2023
Next filing
06 Nov 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SKYE Stock Option (Right to Buy) Award $0 +1,472,692 $0.000000 1,472,692 25 Aug 2023 Common Stock 1,472,692 $0.0140 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option grant shall be exercisable for a price of $0.014 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the one year period beginning August 24, 2023.